Deadline: September 30, 2025
Pfizer INDovation invites innovative MedTech start-ups in India to apply for its program aimed at supporting the development, validation, and deployment of scalable healthcare solutions that improve access to screening, diagnosis, monitoring, and treatment enablement.
Pfizer INDovation focuses on supporting start-ups working on innovative MedTech solutions in areas of public health significance, including Non-Communicable Diseases (NCDs), Oncology, Maternal & Child Health, and Immunisation. The program targets solutions that enable early screening, efficient monitoring, timely diagnosis, effective management of disease, cost-effective healthcare delivery, real-world evidence generation, and public health deployment in low-resource settings.
Article Body: India’s healthcare system faces significant challenges with unevenly distributed resources, limited access to medical professionals, and a shortage of diagnostic infrastructure, resulting in delayed diagnoses, missed intervention opportunities, and high out-of-pocket expenditures. MedTech start-ups have the potential to address these gaps but require support for clinical validation, regulatory approval, and deployment in public health settings.
Pfizer INDovation offers two application tracks to cater to start-ups at different stages of product development. The Incubation Track is for start-ups with clinical study-ready prototypes and provides support for clinical validation, regulatory approvals, and transitioning from prototype to market-ready solutions. The Deployment Track targets start-ups with market-ready products that have obtained regulatory approvals, facilitating pilot deployments in Ayushman Arogya Mandirs and generating real-world evidence on clinical utility and impact.
Eligible start-ups must meet track-specific criteria. For the Incubation Track, this includes completed pre-clinical or clinical equivalence studies, established quality assurance processes, and preliminary clinical trial plans. The Deployment Track requires regulatory certification for public health deployment, the capacity to manufacture and deliver products at scale, and willingness to engage with end-users for training and feedback collection.
Selected start-ups will receive grant support of up to 60 lakh INR per track, expert mentorship, access to pilot deployment sites, support for clinical validation and regulatory readiness, and opportunities to secure further investment. Through these offerings, the program seeks to accelerate innovations that address critical public health challenges such as delayed detection of NCDs, late-stage cancer diagnoses, maternal and neonatal health risks, and gaps in immunisation coverage.
Applications for Pfizer INDovation open on September 2nd, 2025, with a submission deadline of September 30th, 2025. Shortlisted candidates will participate in a jury round in November 2025, followed by the announcement of winners later that month.
For more information, visit Social Alpha.
